CD74 expression and its therapeutic potential in thyroid carcinoma

NCU Institutional Repository > 生醫理工學院 > 生醫科學與工程學系 > 期刊論文 > Item 987654321/102702

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.lib.ncu.edu.tw/handle/987654321/102702

题名:	CD74 expression and its therapeutic potential in thyroid carcinoma
作者:	許藝瓊;Cheng, Shih-Ping;Liu, Chien-Liang;Chen, Ming-Jen;Chien, Ming-Nan;Leung, Ching-Hsiang;Lin, Chi-Hsin;Hsu, Yi-Chiung;Lee, Jie-Jen
贡献者:	生醫理工學院生醫科學與工程學系
关键词:	Antibodies - pharmacology;Antigens, Differentiation, B-Lymphocyte - genetics;Antigens, Differentiation, B-Lymphocyte - immunology;Antigens, Differentiation, B-Lymphocyte - metabolism;Carcinoma - metabolism;Carcinoma - pathology;Carcinoma, Papillary;Cell Line, Tumor;Cell Movement;Gene Expression Regulation, Neoplastic;Histocompatibility Antigens Class II - genetics;Histocompatibility Antigens Class II - immunology;Histocompatibility Antigens Class II - metabolism;Humans;Intramolecular Oxidoreductases - genetics;Intramolecular Oxidoreductases - metabolism;Macrophage Migration-Inhibitory Factors - genetics;Macrophage Migration-Inhibitory Factors - metabolism;Thyroid Cancer, Papillary;Thyroid Gland - metabolism;Thyroid Neoplasms - metabolism;Thyroid Neoplasms - pathology;Transcriptome;Tumor Burden;Wound Healing
日期:	2015-04-01
上传时间:	2026-04-23 11:15:16 (UTC+8)
出版者:	BioScientifica Ltd.;England: Bioscientifica Ltd
摘要:	摘要： CD74, the invariant chain of major histocompatibility complex class II, is also a receptor for macrophage migration inhibitory factor (MIF). CD74 and MIF have been associated with tumor progression and metastasis in hematologic and solid tumors. In this study, we found that 60 and 65% of papillary thyroid cancers were positive for CD74 and MIF immunohistochemical staining respectively. Anaplastic thyroid cancer was negative for MIF, but mostly positive for CD74 expression. Normal thyroid tissue and follicular adenomas were negative for CD74 expression. CD74 expression in papillary thyroid cancer was associated with larger tumor size (P=0.043), extrathyroidal invasion (P=0.021), advanced TNM stage (P=0.006), and higher MACIS score (P=0.026). No clinicopathological parameter was associated with MIF expression. Treatment with anti-CD74 antibody in thyroid cancer cells inhibited cell growth, colony formation, cell migration and invasion, and vascular endothelial growth factor secretion. In contrast, treatment with recombinant MIF induced an increase in cell invasion. Anti-CD74 treatment reduced AKT phosphorylation and stimulated AMPK activation. Our findings suggest that CD74 overexpression in thyroid cancer is associated with advanced tumor stage and may serve as a therapeutic target. 其他題名： Endocr Relat Cancer 出版者： England: Bioscientifica Ltd 出版日期： 2015-04-01 出處： Endocrine-Related Cancer, 2015-04, Vol.22 (2), p.179-190 版權： 2015 Society for Endocrinology 版權： 2015 Society for Endocrinology. 識別號： ISSN: 1351-0088 識別號： ISSN: 1479-6821 識別號： EISSN: 1479-6821 識別號： DOI: 10.1530/ERC-14-0269 識別號： PMID: 25600560
显示于类别:	[生醫科學與工程學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	24	检视/开启

在NCUIR中所有的数据项都受到原著作权保护.

社群 sharing

数据加载中.....